Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

This study has been completed.

Sponsor:

Information provided by:

Clinical Trial Agency of HIV Study Group

ClinicalTrials.gov Identifier:

NCT00256828

First received: November 21, 2005

Last updated: October 15, 2007

Last verified: November 2005

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	November 2006
Estimated Primary Completion Date:	No date given

No publications provided by Clinical Trial Agency of HIV Study Group

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis. 2008 Oct 15;47(8):1083-92.

To Top